Oncternal Therapeutics Inc (ONCT)

$0.53 -0.17 (-24.11%)
Market Cap 1.56M
Revenue (ttm) 790,000.00
Net Income (ttm) -39.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -4,997.47%
Debt to Equity Ratio 0.00
Volume 702,100
Avg Vol 146,574
Day's Range N/A - N/A
Shares Out 2.96M
Stochastic %K 0%
Beta 1.18
Analysts Hold
Price Target $2.00
Drew613
Drew613 Jul. 1 at 8:58 PM
$ONCT Ok, it’s mid-year now. Any update?
1 · Reply
laurent_fr
laurent_fr Apr. 22 at 4:39 PM
$ONCT Hello Anyone to sell ONCT shares?
1 · Reply
joe77w
joe77w Mar. 6 at 3:11 AM
$ONCT https://m.aktiencheck.de/analysen/Artikel-Oncternal_Therapeutics_Nears_Final_Liquidation_Phase-19506697
2 · Reply
joe77w
joe77w Dec. 30 at 7:48 PM
$ONCT I have read it, lets Hope some money back in july 2026
1 · Reply
RandomUser1001
RandomUser1001 Dec. 30 at 7:30 PM
$ONCT https://www.oncternal.com/assets/letter-to-shareholders-12-23-25.pdf
0 · Reply
joe77w
joe77w Dec. 21 at 8:59 AM
$ONCT still no update about CVRs, liquidation... Hmm...
1 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 10 at 2:53 PM
$ONCT $RATSFARTS Small profift....you are a joke and a liar.
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 10 at 2:51 PM
$OPK $ONCT $RATSFARTS Bro you and your ho do not own a single share of either of these stocks. You are a no body here.
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 8 at 11:20 AM
$ONCT $OPK @Ratsfarts Bro you are such a liar. You do not own a single share of ONCT or OPK. You are a total fraud. Buyers beware of this fool. And Rastfarts take your total portfolio of $500 and put it in a a CD because you clearly do not know how to invest in stocks.
0 · Reply
ForestFoxes
ForestFoxes Sep. 21 at 3:57 PM
It's Sunday morning ⛅️ and I've been reflective ☺️☕️ I hope you all won't mind this cross post between $BCRX $GRTS $ONCT $ORGN and $TRVN which I've tied together in the attached comparative Nasdaq chart. My notes appear towards the right-hand edge of the image. There is also a request from me related to ANVS in red 🟥 I hope that is useful for you and someone you know. I'm short on time, but please revisit this post later for additional information related to my request. Take care and have a very nice, Sunday 🌻 #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #NIH #NIA #SEC
1 · Reply
Latest News on ONCT
Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

Jul 1, 2025, 8:00 AM EDT - 1 year ago

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

Mar 7, 2025, 4:05 PM EST - 1 year ago

Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 2 years ago

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Aug 1, 2024, 4:05 PM EDT - 2 years ago

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

Jul 11, 2024, 4:05 PM EDT - 2 years ago

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

May 30, 2024, 4:05 PM EDT - 2 years ago

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

May 9, 2024, 4:01 PM EDT - 2 years ago

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

May 2, 2024, 4:05 PM EDT - 2 years ago

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

May 1, 2024, 9:00 AM EDT - 2 years ago

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Apr 18, 2024, 9:00 AM EDT - 2 years ago

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Mar 15, 2024, 9:00 AM EDT - 2 years ago

Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 7, 2024, 4:01 PM EST - 2 years ago

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 4:05 PM EST - 2 years ago

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

Feb 6, 2024, 4:30 PM EST - 2 years ago

Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Jan 8, 2024, 9:00 AM EST - 2 years ago

Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces Reverse Stock Split

Jan 4, 2024, 9:00 AM EST - 2 years ago

Oncternal Therapeutics Announces Reverse Stock Split

Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Dec 26, 2023, 9:00 AM EST - 2 years ago

Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Nov 9, 2023, 4:01 PM EST - 2 years ago

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Oct 26, 2023, 9:00 AM EDT - 2 years ago

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Oct 25, 2023, 9:00 AM EDT - 2 years ago

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

Oct 5, 2023, 4:01 PM EDT - 2 years ago

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

Sep 7, 2023, 9:00 AM EDT - 3 years ago

Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

Aug 10, 2023, 4:01 PM EDT - 3 years ago

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results

Aug 3, 2023, 4:30 PM EDT - 3 years ago

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results

Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer

Aug 3, 2023, 4:05 PM EDT - 3 years ago

Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma

Jun 6, 2023, 4:01 PM EDT - 3 years ago

Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma

Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference

May 31, 2023, 5:00 PM EDT - 3 years ago

Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

May 4, 2023, 4:01 PM EDT - 3 years ago

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results

Apr 27, 2023, 5:00 PM EDT - 3 years ago

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results

Oncternal Therapeutics Participating in Oppenheimer & Co.'s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors

Apr 13, 2023, 5:00 PM EDT - 3 years ago

Oncternal Therapeutics Participating in Oppenheimer & Co.'s Virtual Fireside Chat: Discussion of ROR1 CAR T Cell Therapy in Hematological Malignancies and Solid Tumors

Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025

Apr 3, 2023, 4:01 PM EDT - 3 years ago

Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Mar 9, 2023, 4:01 PM EST - 3 years ago

Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results

Mar 2, 2023, 5:00 PM EST - 3 years ago

Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Mar 1, 2023, 5:00 PM EST - 3 years ago

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors

Jan 4, 2023, 4:05 PM EST - 3 years ago

Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022

Dec 10, 2022, 3:00 PM EST - 3 years ago

Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

Nov 3, 2022, 4:01 PM EDT - 3 years ago

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2022 Financial Results

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

Nov 3, 2022, 9:05 AM EDT - 3 years ago

Oncternal Therapeutics to Present Updated Interim Phase 1/2 Data for Zilovertamab in Combination with Ibrutinib in an Oral Session at ASH 2022

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results

Oct 27, 2022, 5:53 PM EDT - 4 years ago

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results

Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma

Oct 3, 2022, 4:31 PM EDT - 4 years ago

Oncternal Therapeutics Receives IND Clearance for ONCT-808, its autologous CAR T Product Candidate Targeting ROR1 for the Treatment of Aggressive B Cell Lymphoma

Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

Sep 27, 2022, 9:00 AM EDT - 4 years ago

Oncternal Therapeutics Initiates Global Registrational Phase 3 Study of Zilovertamab for Patients with MCL

Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Sep 23, 2022, 9:00 AM EDT - 4 years ago

Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Sep 7, 2022, 5:00 PM EDT - 4 years ago

Oncternal Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

Aug 9, 2022, 4:05 PM EDT - 4 years ago

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2022 Financial Results

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results

Aug 2, 2022, 5:00 PM EDT - 4 years ago

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL

Jul 14, 2022, 4:01 PM EDT - 4 years ago

Oncternal Therapeutics Announces Clinical Trial Collaboration to Advance Zilovertamab Phase 3 Study in combination with Ibrutinib for Patients with MCL

Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

Jun 10, 2022, 4:30 PM EDT - 4 years ago

Oncternal Therapeutics Presents New Preclinical Data from its anti-ROR1 Cell Therapy Collaboration with the Karolinska Institutet at the EHA2022 Congress

Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress

Jun 10, 2022, 9:00 AM EDT - 4 years ago

Oncternal Therapeutics Presents Rationale and Plans for its Registrational Phase 3 Study Evaluating Zilovertamab in Combination with Ibrutinib at the EHA 2022 Congress

Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022

Jun 2, 2022, 9:00 AM EDT - 4 years ago

Oncternal Therapeutics to Participate in the Jefferies Healthcare Conference 2022

Drew613
Drew613 Jul. 1 at 8:58 PM
$ONCT Ok, it’s mid-year now. Any update?
1 · Reply
laurent_fr
laurent_fr Apr. 22 at 4:39 PM
$ONCT Hello Anyone to sell ONCT shares?
1 · Reply
joe77w
joe77w Mar. 6 at 3:11 AM
$ONCT https://m.aktiencheck.de/analysen/Artikel-Oncternal_Therapeutics_Nears_Final_Liquidation_Phase-19506697
2 · Reply
joe77w
joe77w Dec. 30 at 7:48 PM
$ONCT I have read it, lets Hope some money back in july 2026
1 · Reply
RandomUser1001
RandomUser1001 Dec. 30 at 7:30 PM
$ONCT https://www.oncternal.com/assets/letter-to-shareholders-12-23-25.pdf
0 · Reply
joe77w
joe77w Dec. 21 at 8:59 AM
$ONCT still no update about CVRs, liquidation... Hmm...
1 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 10 at 2:53 PM
$ONCT $RATSFARTS Small profift....you are a joke and a liar.
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 10 at 2:51 PM
$OPK $ONCT $RATSFARTS Bro you and your ho do not own a single share of either of these stocks. You are a no body here.
0 · Reply
This_Bull_Is_Retired
This_Bull_Is_Retired Dec. 8 at 11:20 AM
$ONCT $OPK @Ratsfarts Bro you are such a liar. You do not own a single share of ONCT or OPK. You are a total fraud. Buyers beware of this fool. And Rastfarts take your total portfolio of $500 and put it in a a CD because you clearly do not know how to invest in stocks.
0 · Reply
ForestFoxes
ForestFoxes Sep. 21 at 3:57 PM
It's Sunday morning ⛅️ and I've been reflective ☺️☕️ I hope you all won't mind this cross post between $BCRX $GRTS $ONCT $ORGN and $TRVN which I've tied together in the attached comparative Nasdaq chart. My notes appear towards the right-hand edge of the image. There is also a request from me related to ANVS in red 🟥 I hope that is useful for you and someone you know. I'm short on time, but please revisit this post later for additional information related to my request. Take care and have a very nice, Sunday 🌻 #CFODive #MauraWebberSadovi #StatNews #AdamFeuerstein #StephenSedgwickCNBC #ENDALZ #FDA_Drug_Info #NIH #NIA #SEC
1 · Reply
Bear_Inspector
Bear_Inspector Aug. 19 at 8:12 PM
$BCTX $CLRB $NBSE $ONCT this guy @ZhaoSonsWealth was pumping the fuck out of TGL. Now GLMD? 😆 🤣 😂
0 · Reply
Bobby_J_Bomb
Bobby_J_Bomb Jul. 18 at 3:16 AM
$ONCT has anyone reached out?
1 · Reply
joe77w
joe77w Jul. 10 at 4:27 PM
$ONCT when we Will get paid? How much? Still no details or CVR in my account.
0 · Reply
joe77w
joe77w Jul. 2 at 11:23 AM
$ONCT so at least 1 usd per share in liquidation assuming whole 3 mln usd earned due to asset sale go to commons, not taking into account any cash left in balance sheets before asset sale. If ph3 fully enrolled upto 5 mln per usd or another 1.6 usd per share/cvr
0 · Reply
joe77w
joe77w Jul. 1 at 9:36 PM
$ONCT https://www.stocktitan.net/news/ONCT/oncternal-therapeutics-announces-the-sale-of-select-development-jk7cn5431ynm.html
0 · Reply
HemDog
HemDog Jul. 1 at 9:05 PM
$ONCT Don - Any word on the disposition of 534?
2 · Reply
Komo1
Komo1 Jul. 1 at 5:39 PM
$ONCT News https://www.globenewswire.com/news-release/2025/07/01/3108259/0/en/Oncternal-Therapeutics-Announces-the-Sale-of-Select-Development-Programs-and-the-Wind-Down-of-its-Operations.html
0 · Reply